Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. Read more about Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. Read more about Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.
Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. Read more about Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment.
LYN- and AIRE-mediated tolerance checkpoint defects synergize to trigger organ-specific autoimmunity. Read more about LYN- and AIRE-mediated tolerance checkpoint defects synergize to trigger organ-specific autoimmunity.
Tie1 controls angiopoietin function in vascular remodeling and inflammation. Read more about Tie1 controls angiopoietin function in vascular remodeling and inflammation.
Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. Read more about Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation.
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. Read more about Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. Read more about Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
The bright side of dark matter: lncRNAs in cancer. Read more about The bright side of dark matter: lncRNAs in cancer.
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Read more about Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
